Ampio Pharmaceutical's FDA application for Ampion clinical study to treat COVID-19 ARDS on TV

Ampio Pharmaceutical's FDA application for Ampion clinical study to treat COVID-19 ARDS on TV

ENGLEWOOD -- Ampio Pharmaceuticals, Inc . (NYSE American: AMPE) announced it was featured on aFOXTV segment titled, "Englewoodpharmaceutical company looking to treat COVID-19 patients with... Read More

Friday April 3, 2020 0 comments Tags: Englewood, Ampio Pharmaceuticals, Ampion, Michael Macaluso, FDA, COVID-19, ARDS

Ampio prepares FDA protocol to study Ampion as treatment for COVID-19 Acute Respiratory Distress

Ampio prepares FDA protocol to study Ampion as treatment for COVID-19 Acute Respiratory Distress

ENGLEWOOD -- Ampio Pharmaceuticals, Inc . (NYSE American: AMPE) announced it is preparing an expanded access FDA protocolto study potential benefit of nebulized treatment with Ampion in SARS-Cov-2... Read More

Wednesday March 25, 2020 0 comments Tags: Englewood, Ampio Pharmaceuticals, Ampion, COVID-19

Ampio updates regulatory status for Ampion drug

Ampio updates regulatory status for Ampion drug

ENGLEWOOD -- Ampio Pharmaceuticals, Inc . (NYSE MKT: AMPE) announced it met with the FDA on Dec. 12 to discuss final guidance to achieve regulatory approval for its osteoarthritis drug Ampion.... Read More

Friday December 14, 2018 0 comments Tags: Englewood, Ampio Pharmaceuticals, Ampion

Ampio provides update on Ampion regulatory review

Ampio provides update on Ampion regulatory review

ENGLEWOOD -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) reports favorable regulatory and peer-review on the status of Ampion, the companys drug for osteoarthritis of the knee. ... Read More

Tuesday November 27, 2018 0 comments Tags: Englewood, Ampio Pharmaceuticals, Ampion

Ampio updates Ampion regulatory progress

Ampio updates Ampion regulatory progress

ENGLEWOOD -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) is providing an update of the regulatory and clinical path activities required to file a Biologics License Application (BLA) for Ampion... Read More

Monday November 12, 2018 0 comments Tags: Englewood, Ampio Pharmaceuticals, Ampion, Mike Macaluso

Ampio: Ampion achieves major decrease in patient osteoarthritis knee pain

Ampio: Ampion achieves major decrease in patient osteoarthritis knee pain

ENGLEWOOD -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) reported that the Phase 3 clinical trial of Ampion met its primary endpoint with 71% of Ampion treated patients meeting the... Read More

Friday December 15, 2017 0 comments Tags: Englewood, Ampio Pharmaceuticals, Ampion, Michael Macaluso

Ampio Pharmaceuticals announces allowance of composition and methods patent for Ampion

Ampio Pharmaceuticals announces allowance of composition and methods patent for Ampion

ENGLEWOOD -- Ampio Pharmaceuticals, Inc . (NYSE MKT: AMPE) today announced the allowance of an important composition and methods patent in the U.S. complimenting a series of patents on Ampion... Read More

Tuesday August 8, 2017 0 comments Tags: Englewood, Ampio Pharmaceuticals, Michael Macaluso, Ampion

Ampio Pharmaceuticals selling $6.3M in stock to fund Ampion clinical tests

Ampio Pharmaceuticals selling $6.3M in stock to fund Ampion clinical tests

ENGLEWOOD -- A mpio Pharmaceuticals, Inc. (NYSE MKT: AMPE) announced it has entered into a securities purchase agreement with investors providing for the registered sale of approximately... Read More

Monday June 5, 2017 0 comments Tags: Englewood, Ampio Pharmaceuticals, Ampion